Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy

Suzuki, Hitoshi; Novák, Jan

doi:10.3390/jcm11154378

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it can be hypothesized that in the future, these drugs could be used in a synergistic manner so as to target multiple disease pathways. Indeed, these various strategies focus on inhibiting signaling pathways, depleting plasma cells, clearing IgA deposits, modulating mucosal immunity, and blocking complement cascades to treat different aspects of IgAN pathogenesis and progression [13,14].…”

Section: New Drugs For Iganmentioning

confidence: 99%

Refractory IgA Nephropathy: A Challenge for Future Nephrologists

Di Leo,

Annese,

Papadia

et al. 2024

Medicina

View full text Add to dashboard Cite

IgA nephropathy (IgAN) represents the most prevalent form of primary glomerulonephritis, and, on a global scale, it ranks among the leading culprits behind end-stage kidney disease (ESKD). Presently, the primary strategy for managing IgAN revolves around optimizing blood pressure and mitigating proteinuria. This is achieved through the utilization of renin–angiotensin system (RAS) inhibitors, namely, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). As outlined by the KDIGO guidelines, individuals who continue to show a persistent high risk of progressive ESKD, even with comprehensive supportive care, are candidates for glucocorticoid therapy. Despite these therapies, some patients have a disease refractory to treatment, defined as individuals that present a 24 h urinary protein persistently >1 g after at least two rounds of regular steroids (methylprednisolone or prednisone) and/or immunosuppressant therapy (e.g., mycophenolate mofetil), or who do not tolerate regular steroids and/or immunosuppressant therapy. The aim of this Systematic Review is to revise the current literature, using the biomedical database PubMed, to investigate possible therapeutic strategies, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, fecal microbiota transplantation, as well as blockade of complement components.

show abstract

Section: New Drugs For Iganmentioning

confidence: 99%

Refractory IgA Nephropathy: A Challenge for Future Nephrologists

Di Leo,

Annese,

Papadia

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…IgA nephropathy is characterized by the deposition of IgA immune complexes in the mesangial region of glomeruli, leading to inflammation and progressive fibrosis. The primary clinical manifestation of IgA nephropathy is gross hematuria with or without proteinuria, but it can also produce asymptomatic microscopic hematuria and slowly progressive renal dysfunction (1,2).…”

Section: Introductionmentioning

confidence: 99%

Biomarkers in IgA nephropathy; an update to recent data

et al. 2023

View full text Add to dashboard Cite

Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.

show abstract

“…Elio G Carmona et al identified a common genetic risk locus for KD and IgAV through a cross-phenotype meta-analysis (Sugiyama et al, 2020). Hitoshi Suzuki et al strongly suggest that IgAN and IgA vasculitis with nephritis (IgA-VN) share similar signs and that galactose deficiency IgA1 plays a very important role in the pathogenesis of both (Suzuki et al, 2018;Suzuki and Novak, 2022). In conclusion, IgAN, IgAV and KD are all immune complex deposition diseases, but in addition, they may be closely related to genetic factors, environmental factors, immune function and other factors that affect the pathogenesis, but it is still unclear at present.…”

Section: Introductionmentioning

confidence: 99%

Landscape of intestinal microbiota in patients with IgA nephropathy, IgA vasculitis and Kawasaki disease

Fan

Song

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

ObjectiveTo explore the common differential flora of IgAN, Kawasaki disease and IgA vasculitis by screening and analyzing the differential intestinal flora between the three disease groups of IgAN, Kawasaki disease and IgA vasculitis and their healthy controls.MethodsPapers on 16srRNA sequencing-related intestinal flora of IgAN, Kawasaki disease and IgA vasculitis were searched in databases, the literature was systematically collated and analysed, the original data was download from the relevant databases, and then the operational taxonomic unit and species classification analysis were performed. Besides, Alpha diversity analysis and Beta diversity analysis were performed to screen for IgAN, Kawasaki disease and I1gA vasculitis groups and finally compare the common intestinal differential flora among the three groups.ResultsAmong the common differential flora screened, Lachnospiracea_incertae_sedis was lower in both the IgAN and Kawasaki disease groups than in the respective healthy controls; Coprococcus was low in the IgAN group but high in the IgA vasculitis group. Fusicatenibacter was lower in both the Kawasaki disease and IgA vasculitis groups than in their respective healthy controls, and Intestinibacter was low in the Kawasaki disease group, but its expression was high in the IgA vasculitis group.ConclusionThe dysbiosis of the intestinal flora in the three groups of patients with IgAN, Kawasaki disease and IgA vasculitis, its effect on the immunity of the organism and its role in the development of each disease group remain unclear, and the presence of their common differential flora may further provide new ideas for the association of the pathogenesis of the three diseases.

show abstract

Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy

Abstract: IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide [...]

Cited by 4 publications

References 35 publications

Refractory IgA Nephropathy: A Challenge for Future Nephrologists

Refractory IgA Nephropathy: A Challenge for Future Nephrologists

Biomarkers in IgA nephropathy; an update to recent data

Landscape of intestinal microbiota in patients with IgA nephropathy, IgA vasculitis and Kawasaki disease

Contact Info

Product

Resources

About